跳至主要内容
临床试验/NCT01602900
NCT01602900已完成1 期

An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain PDE4 Engagement, Pharmacokinetics and Safety of Single Oral Doses of GSK356278, Using 11C-(R)-Rolipram as a PET Ligand(s)

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2011年11月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
8
试验地点
1
主要终点
Positron Gamma-ray emmision & voxel counts

研究概览

简要总结

This study will investigate if a new experimental drug to treat Huntington's Disease gets into the brain. If it does get into the brain the study will explore the relationship between the amount of drug in the brain and the amount of drug in the blood. The study will involve healthy male volunteers.

详细描述

This is an open label, non-randomized, adaptive design PET occupancy study in healthy adult males. The primary aim of this study is to describe the relationship between plasma concentrations and brain PDE4 occupancy of GSK356278 over time. Up to 24 healthy volunteers may be administered single doses of GSK356278 in order to obtain 12 evaluable complete data sets of occupancy estimates. This study will help to optimize the dose selection for future clinical studies with GSK356278.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male volunteer, aged 22-55 years.
  • Normal blood pressure, laboratory values, and body mass index
  • Willing to agree to study procedures & contraception requirements
  • Capable of giving written informed consent

排除标准

  • Any evidence of disease that would preclude participation in the clinical study (includes sexually transmitted diseases, exessive alcohol consumption, and substance abuse).
  • Previously involved in another clinical trial within 3 months prior to scheduled administration of study drug
  • Suffers from claustrophobia
  • Any contraindications for MRI scanning (e.g. pacemaker, metal implants or fillings)

研究组 & 干预措施

GSK356278

Experimental

Investigational drug

干预措施: GSK356278 (Drug)

GSK356278

Experimental

Investigational drug

干预措施: Rolipram (Drug)

结局指标

主要结局

Positron Gamma-ray emmision & voxel counts

时间窗: 60 minutes

Brain regions of interest and associated radionuclitide-activity

systemic plasma concentration

时间窗: 24 hours

serial sampling: GSK356278 concentration expressed as mass per unit of volume

次要结局

  • Heart rate - bpm(72 hours)
  • ECG - 12-Lead & Telemetry(24 & 72 hours)
  • Blood pressure - mm/Hg(24 hours)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验